Welcome to the Global Power of Oncology Nursing

The Global Power of Oncology Nursing (GPON) conference is held annually as part of London Global Cancer Week, showcasing the nursing contribution to tackling the global burden of cancer. Nurses share their stories, engage in debates, and celebrate their achievements with colleagues from around the world. Most nurse presenters live and work in low- and middle-income countries (LMIC) and focus on solutions to improve cancer care in a world where universal health coverage is far from a reality. Nurses can and do make a huge impact on the burden of cancer, often being the first and only point of care in their communities. However, there is a huge shortage of trained oncology nursing workforce, affecting both the work nurses can do and patient care.

NEWS

REVISIT GPON 2021

This year we have an action-packed programme over 3 days; nurses recounting their stories of the last year, when ‘Compassion, Innovation and Strength’ was unleashed in abundance by all nurses. We send a truly heartfelt thanks to all the nurses and colleagues around the globe who worked tirelessly throughout the COVID-19 pandemic and/or Conflict and/or Climate Change. How is that possible? We will unmask at our truly engaging programme with many poignant experiences are shared and debated, punctuated by music and dance, and some fun in the videos. Based in the UK, we kick off on Day 1 London time, then to the East (of the UK) on Day 2 with Day 3 in ‘the West’ which will be for English and Spanish speakers.

SPONSORS

Educational Sponsor
leo-400-1
Event Partner
paxman-logo-sq400
Event Sponsor
Event Sponsor
takeda-logo
Event Sponsor
Event Sponsor
Event Sponsor

COMMUNITY

Testimonials

“The speakers were all inspirational, sharing their experiences of working in extraordinary circumstances around the world. The importance of compassion in cancer nursing was truly reinforced".​
Dr Verna Lavender
Guy's and St Thomas' NHS Foundation Trust
“The speakers were all inspirational, sharing their experiences of working in extraordinary circumstances around the world. The importance of compassion in cancer nursing was truly reinforced".​
Dr Verna Lavender
Guy's and St Thomas' NHS Foundation Trust

Mailing List

Stay up to date with the latest GPON news and events by joining our mailing list. 

GPON will not pass on your submitted information to third parties. You can unsubscribe from our mailing list at anytime.

Twitter

Roche

Roche is the world’s largest biotech company and a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. Roche has created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast.

LEO Pharma

LEO Pharma is a leader in thrombosis with a specific focus on cancer associated thrombosis.
We have worked with healthcare professionals to care for people with thrombosis for over 80 years. We strive to improve lives with high ethics and holistic support, setting new standards of care.

LEO Pharma headquarters are in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
For more information please visit:

 https://www.leo-pharma.co.uk/Home/Our-focus/Thrombotic-Conditions.aspx

Paxman

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced alopecia (CIA).

As Healthcare Professionals, you understand the extent to which CIA can compromise a patient’s quality of life, often negatively impacting on body image, self-esteem and depriving patients of their privacy. Sometimes, the prospect of CIA can cause patients to refuse treatment.

Proven to be an effective way of combatting CIA, scalp cooling can result in a high level of retention or completely preserve the hair. Scalp cooling has also been shown in studies to encourage better and faster hair regrowth following completion of chemotherapy treatment. For patients, this means the opportunity to regain some control, maintain privacy and encourage a positive attitude towards treatment. The NCCN® Clinical Practice Guidelines in oncology (Version 1.2019) recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer who are receiving chemotherapy to reduce the incidence of CIA.

Investing in scientific testing and development has allowed Paxman to attain the highest levels of technical precision and clinical efficacy. Clinical trials, research and health service dialogue over the past several decades have been extensive – this remains ongoing. PAXMAN have grown to become the world’s leading manufacturer and supplier of scalp cooling equipment, with close to 4,000 Paxman Scalp Cooling Systems installed in over 35 global markets. However, with cancer touching the lives of more people than ever before, the mission is far from over.

Let’s all work together to chase zero hair loss during chemotherapy and provide patients with a sense of normalcy during one of the most difficult times of their lives.

Please visit www.paxmanscalpcooling.com for detailed clinical and scientific information, www.coldcap.com for our patient guide or e-mail us at info@paxmanscalpcooling.com

Rosemont

At Rosemont our mission is to be a rapid developer, reliable manufacturer and global supplier of novel-delivery, patient-focused medicines. Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We have a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products. Our UK range also includes 9 products licensed for use with PEG/NG tubes. We are seeking to expand our range of medicines and convert our ‘specials’ to licensed products wherever possible. In addition to our extensive range of liquid medicines, Rosemont also provides a wide variety of resources designed to support healthcare professionals deliver the best possible care for their patients. Resources include further information on swallowing difficulties and product education.

www.rosemontpharma.com

Takeda

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We are structured within Takeda to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. With demonstrated leadership in the treatment of hematologic cancers and solid tumors, we propel cutting-edge science around the power of innate immunity to enhance and broaden the impact of immunotherapy.

We complement our deep in-house expertise with symbiotic partnerships to unlock promising science wherever it emerges.

Incyte

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, USA, by a team of research scientists, chemists and biologists working in immunology. Today, we employ approximately 1500 people and have operations in the US, Europe and Japan.

Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.

The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.

B Braun

B. Braun stands for over 180 years of innovative solutions in healthcare, with a passionate workforce of ambitious people who contribute to the company ethos of protecting and improving the health of people around the world.

Headquartered in Melsungen, Germany, B. Braun is one of the world’s leading providers and manufacturers of high quality product systems and service.

https://www.bbraun.co.uk/en/products-and-therapies/infusion-therapy/tevadaptor-.html